ArticleCancer medicine2021

Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.

Kazuyuki Numakura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.